adminBy Ben Glickman
Tyra Biosciences said it received Rare Pediatric Disease Designation from regulators for its potential treatment for a form of dwarfism.
The Carlsbad, Calif.-based biotechnology company said Thursday the U.S. Food and Drug Administration had granted the designation to TYRA-300 as a potential treatment of achondroplasia.
The company said achondroplasia is the most common form of dwarfism and has limited available therapies.
Tyra plans to submit an Investigational New Drug application to the FDA in the second half of 2024, which would allow the company to begin a Phase 2 clinical trial examining dose cohorts.
RPD designation is given by the FDA to potential drugs to treat rare serious or life-threatening diseases which primarily affect children.
Write to Ben Glickman at [email protected]
Read the full article here
